Ann: Change in substantial holding-BLT.AX, page-24

I'm glad Carl is upbeat. Too bad shareholders don't share his enthusiasm.  

At minimum, a well versed interim report regarding the full efficacy of TT-034 patients up until the last one would be a boon to the sp, a boost to shareholder confidence, and a boost of confidence to the technology. But instead we wait months for a spit of news regarding a CEO, in-vivo data at the end of the year (possibly), and an all-time low of 10.5c.

At least when I decide to fully jump back in again, the share price will be starving for my contribution. Why does every OTHER company or paper relate to how ddRNAi is effective at this and that, but a company who actually used it in a clinical trial can't come up with meaningful data.

Hit this link and you'll know what I mean. . Lol!